Moreover think it is a safe back of the envelope extrapolation to annualise monthly revenue to get a feel of the yearly run rate we are tracking at. WE should still be in growth phase which would more than offset any unfavorable movement in % refill uptake.
By December of this year (6 months time), BOT should honestly be on a run rate to delivery $300m (ie $25M monthly revenue in Dec or 40,000 scripts in that month)
great news of this is that this only represents 1% of the 3.7M imminent target market. And even better news is that we know that that target market is substantially bigger and does not account for newly diagnosed patients since that data was captured which is easily more than 12-18 months out of date.
BOT Price at posting:
30.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)